Distribution of organic matter, phytopigments and heterotrophic bacteria along the salinity gradient in the estuaries of small rivers of the Tatar Strait basin

Distribution of total organic matter and its dissolved and suspended forms was investigated in two small estuaries with different morphometric characteristics, as Muchke and Toki Lakes, in late July 2014 at the low tide phase. The time of survey was distinguished by low river discharge and high tides. Content of all forms of organic matter and hydrocarbons was higher in the estuarine waters, as compared with fresh river water, regardless of salinity. The dissolved form prevailed (79.7-98.6 % of the total organic matter content) with concentrations of 5.2-35.7 mg/l. Chlorophyll a dominated (up to 87 %) among phytopigments in both estuaries that corresponded to active development of microalgae. Toki Lake was distinguished by higher productivity and microplankton abundance. On the contrary, allochthonous organic matter was more abundant in Muchke Lake, where interrelation between destructors (heterotrophic bacteria number) and primary producers (Chl a concentration) was observed. Oil-oxidizing microorganisms were up to 60 % of the heterotrophic bacteria number. The hydrocarbons content exceeded the maximal permissible level: 3.6 and 4.5 MPL in Muchke and Toki Lakes, respectively. Both estuaries were subjected to chronic hydrocarbon pressure

FermiGrid - experience and future plans

Fermilab supports a scientific program that includes experiments and scientists located across the globe. In order to better serve this community, Fermilab has placed its production computer resources in a Campus Grid infrastructure called 'FermiGrid'. The FermiGrid infrastructure allows the large experiments at Fermilab to have priority access to their own resources, enables sharing of these resources in an opportunistic fashion, and movement of work (jobs, data) between the Campus Grid and National Grids such as Open Science Grid and the WLCG. FermiGrid resources support multiple Virtual Organizations (VOs), including VOs from the Open Science Grid (OSG), EGEE and the Worldwide LHC Computing Grid Collaboration (WLCG). Fermilab also makes leading contributions to the Open Science Grid in the areas of accounting, batch computing, grid security, job management, resource selection, site infrastructure, storage management, and VO services. Through the FermiGrid interfaces, authenticated and authorized VOs and individuals may access our core grid services, the 10,000+ Fermilab resident CPUs, near-petabyte (including CMS) online disk pools and the multi-petabyte Fermilab Mass Storage System. These core grid services include a site wide Globus gatekeeper, VO management services for several VOs, Fermilab site authorization services, grid user mapping services, as well as job accounting and monitoring, resource selection and data movement services. Access to these services is via standard and well-supported grid interfaces. We will report on the user experience of using the FermiGrid campus infrastructure interfaced to a national cyberinfrastructure--the successes and the problems

FermiGrid

As one of the founding members of the Open Science Grid Consortium (OSG), Fermilab enables coherent access to its production resources through the Grid infrastructure system called FermiGrid. This system successfully provides for centrally managed grid services, opportunistic resource access, development of OSG Interfaces for Fermilab, and an interface to the Fermilab dCache system. FermiGrid supports virtual organizations (VOs) including high energy physics experiments (USCMS, MINOS, D0, CDF, ILC), astrophysics experiments (SDSS, Auger, DES), biology experiments (GADU, Nanohub) and educational activities

High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity

Aim. To study the significance of monitoring high-sensitivity troponin I (hs-cTnI) for predicting anthracycline-induced left ventricular (LV) dysfunction in the treatment of breast cancer in patients with moderate and low risk of cardiotoxicity (CT).Material and methods. The study involved 49 patients with breast cancer aged 50±10 years who underwent neoadjuvant or adjuvant chemotherapy, which included doxorubicin at a course dose of 60 mg/m2 and an average cumulative dose of 251±60 mg/m2. The level of hs-cTnI was determined by an ultrasensitive method before the start of chemotherapy, after each course of anthracyclines and in 18 patients before the administration of anthracyclines. The level of hscTnI >0,017 ng/ml was considered elevated. Echocardiography was performed before the start of chemotherapy, after the end of anthracycline therapy, and every 3 months for 12 months thereafter. CT was defined as a decrease in LV ejection fraction (EF) by ≥10% to <53%.Results. CT risk before chemotherapy was considered low and moderate in 96% of patients. An increase in hs-сTnI was detected ≥1 times in 56,8% of patients: before chemotherapy — in 13,5%, after 1 and 2 courses of anthracycline therapy — in 13,9%, after 3, 4, 5 and 6 courses — in 44%, 62%, 71% and 66% of patients, respectively. The levels of hs-cTnI before and after administration of anthracyclines did not differ significantly. The development of LV dysfunction was observed in 16,3% of patients. There were following prognostic significance of an increase in hs-cTnI at any time of chemotherapy for a decrease in LV EF: sensitivity — 87,5%, specificity — 50%, the positive predictive value — 28%, the negative predictive value — 94,7%. The closest relationship was noted between CT and hs-cTnI value before the start of chemotherapy (β=0,45, p=0,005) and after the 3rd course of anthracycline therapy (β=0,56, p=0,002).Conclusion. An increase in hs-cTnI level before and during anthracycline thera py in patients with a low risk of cardiotoxicity has a prognostic value in relation to the development of left ventricular dysfunction. Hs-cTnI assessment should be performed before the start of therapy, and then starting from the 3rd course of anthracycline therapy in all patients, regardless of the risk of cardiotoxicity

Measurement of the mass difference m(D-s(+))-m(D+) at CDF II

We present a measurement of the mass difference m(D-s(+))-m(D+), where both the D-s(+) and D+ are reconstructed in the phipi(+) decay channel. This measurement uses 11.6 pb(-1) of data collected by CDF II using the new displaced-track trigger. The mass difference is found to be m(D-s(+))-m(D+)=99.41+/-0.38(stat)+/-0.21(syst) MeV/c(2)